{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:42:15Z","timestamp":1789461735919,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.cpcardiol.2023.102236","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T02:47:30Z","timestamp":1701398850000},"page":"102236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: A pilot systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"49","author":[{"given":"Aman","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mah I Kan","family":"Changez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Daoud","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiza","family":"Mushtaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Shamim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Humza","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5101-6024","authenticated-orcid":false,"given":"Gauranga","family":"Mahalwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102236_bib0001","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11883-020-00884-2","article-title":"The knowns and unknowns of contemporary statin therapy for familial Hypercholesterolemia","volume":"22","author":"Pang","year":"2020","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102236_bib0002","first-page":"85","article-title":"Latest updates on lipid management","volume":"26","author":"Egom","year":"2019","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0003","article-title":"Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States","volume":"1","author":"Klimchak","year":"2020","journal-title":"Am J Prevent Cardiol"},{"issue":"25","key":"10.1016\/j.cpcardiol.2023.102236_bib0004","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology\/american heart association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102236_bib0005","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12020-022-03263-w","article-title":"Statin intolerance management: a systematic review","volume":"79","author":"Meza-Contreras","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102236_bib0006","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102236_bib0007","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7326\/M13-2526","article-title":"Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review","volume":"160","author":"Gudzune","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.789931","article-title":"Emerging non-statin treatment options for lowering low-density lipoprotein cholesterol","volume":"8","author":"Bardolia","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"15","key":"10.1016\/j.cpcardiol.2023.102236_bib0009","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0010","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102236_bib0011","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1002\/hsr2.431","article-title":"Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia","volume":"4","author":"Govindaraju","year":"2021","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0012","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.cpcardiol.2023.102236_bib0013","first-page":"195","article-title":"Bempedoic acid: an emerging therapy for uncontrolled low-density lipoprotein (LDL) cholesterol","volume":"10","author":"Pradhan","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0015","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","article-title":"Safety and efficacy of bempedoic acid to reduce LDL cholesterol","volume":"380","author":"Ray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0016","series-title":"American College of Cardiology Annual Scientific Session","article-title":"Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia and high cardiovascular risk: the clear Wisdom trial","author":"Goldberg","year":"2019"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102236_bib0017","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0018","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0019","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102236_bib0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2023.102236_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011662","article-title":"Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance","volume":"8","author":"Laufs","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102236_bib0022","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jama.2023.9696","article-title":"Bempedoic acid for primary prevention of cardiovascular events in statin-intolerant patients","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.cpcardiol.2023.102236_bib0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2023.102236_bib0024","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jacl.2016.03.004","article-title":"Statin intolerance in a referral lipid clinic","volume":"10","author":"Lakey","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"17","key":"10.1016\/j.cpcardiol.2023.102236_bib0025","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Ginsberg HN; european atherosclerosis society consensus panel. statin-associated muscle symptoms: impact on statin therapy-european atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J."},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0027","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S1567-5688(17)30024-7","article-title":"SAMS expert working group. practical aspects in the management of statin-associated muscle symptoms (SAMS)","volume":"26","author":"Laufs","year":"2017","journal-title":"Atheroscler Suppl."},{"issue":"1","key":"10.1016\/j.cpcardiol.2023.102236_bib0028","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacl.2016.10.003","article-title":"Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system","volume":"11","author":"Graham","year":"2017","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.cpcardiol.2023.102236_bib0029","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102236_bib0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0259-7","article-title":"Management of statin intolerance in 2018: still more questions than answers","volume":"18","author":"Toth","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.cpcardiol.2023.102236_bib0031","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102236_bib0032","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.33.498","article-title":"Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human","volume":"33","author":"Sato","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"10.1016\/j.cpcardiol.2023.102236_bib0033","first-page":"212","article-title":"The significance of plasma high density lipoprotein cholesterol (HDLC)","volume":"9","author":"Gupta","year":"2007","journal-title":"Nepal Med Coll J"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280623006539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T02:53:56Z","timestamp":1758941636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280623006539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S0146280623006539"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102236","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and outcomes of Bempedoic acid versus placebo in patients with statin-intolerance: A pilot systematic review and meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102236"}}